Analyses from the International BC Study Group’s clinical trials showed that estrogen receptor-positive BCs maintain a relatively high hazard of recurrence beyond 10 years post-diagnosis [3]; however, the peak hazard for recurrence occurs between 1 and 2 years after treatment. Here, ESR1 is linked to breast cancer.